Danish synthetic biology company Octarine Bio, which produces psilocybin from sugar using a fermentation process, has partnered with Clerkenwell Health, a U.K.-based mental health start-up focused on delivering clinical trials, the two parties have announced.
Story continues below
This advertisement has not loaded yet, but your article continues below.
According to a news release, the partnership should help advance patient access to psychedelic medicines in Europe.
Octarine Bio is backed by institutional investors such as Oskare Capital, The Danish State Growth Fund and a number of angel investors, including Bruce Linton.
The company uses low-cost yeast fermentation to produce psilocybin from sugar, while Clerkenwell Health is focused on clinical research support services and will soon be opening its own research
Read full article on The Growth Op
